AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00246935
- Locations
- 🇯🇵
Nycomed in Japan and Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)
Phase 3
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00246922
- Locations
- 🇯🇵
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00244608
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT00244621
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 235
- Registration Number
- NCT00244595
- Locations
- 🇸🇰
Research Site, Trnava, Slovakia
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
Phase 3
Completed
- Conditions
- Pediatric Hypertension
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 238
- Registration Number
- NCT00244634
- Locations
- 🇸🇰
Research Site, Trnava, Slovakia
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Phase 3
Completed
- Conditions
- Gastroesophageal RefluxHeartburnDyspepsia
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00243724
- Locations
- 🇨🇦
Research Site, Quebec, Canada
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
Phase 1
Completed
- Conditions
- CarcinomaNon-Small-Cell Lung CarcinomaHead and Neck Neoplasms
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT00243347
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00242762
- Locations
- 🇪🇸
Research Facility, Murcia, Spain
🇪🇸Research Site, Sevilla, Spain
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2100
- Registration Number
- NCT00242775
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath